This is our hub for GLP-1 telehealth provider reviews. Each review below evaluates a cash-pay provider on the decisions patients actually make at checkout: what the full price is after dose escalation, what the commitment-tier refund terms look like, what the BBB and Trustpilot record says, and what state regulators and manufacturer lawsuits have established. Our editorial voice is neutral. Each review carries a partnership badge at the top: most reviews on this site have no affiliate or referral relationship with the provider; one review currently has a disclosed partnership, clearly labeled.
How We Review
- Headline price versus real price: the advertised rate is rarely what a standard-dose patient pays. Every review reconstructs the actual month-to-month cost at common doses and notes where dose escalation adds tiered fees.
- Commitment-tier pricing and refunds: multi-month prepay plans drop the effective monthly price but frequently carry non-refundable terms. We document the refund language for every tier we can verify.
- BBB, Trustpilot, and FDA: complaint volume over three years, dominant complaint categories, Trustpilot average across thousands of reviews, and a direct check against the FDA Warning Letters Database on the retrieval date.
- State-level pharmacy action: when a state Department of Health or pharmacy board places restrictions on a provider's affiliated compounding pharmacy, we treat that as a material safety signal and report it prominently.
- Industry lawsuits, in context: Eli Lilly and Novo Nordisk have filed lawsuits against most large compounded-GLP-1 telehealth providers. We note the case, but these are industry-wide and not a customer-impact signal on their own.
Current Reviews
Four full reviews are live, with more in progress. Each links to the full article. One review (OnlineSemaglutide) carries a disclosed partnership; the other three carry no affiliate relationship.
Provider comparison at a glance
A scannable comparison across the four providers currently reviewed. Prices are month-to-month cash-pay at the standard starting dose. Full context, including dose-escalation fees and prepay refund terms, lives in each review.
| Provider | Semaglutide (mo) | Tirzepatide (mo) | BBB | Trustpilot | HMI Rating |
|---|---|---|---|---|---|
| OnlineSemaglutide (disclosed partnership) | $249 M2M / $150 6-mo prepay | $349 M2M / $242 6-mo prepay | No public profile | No public profile | 4.5 / 5 |
| Henry Meds | $297 (injectable) | Higher, dose-tiered | F, 192 complaints | 4.5 ★ / 12,320 | 4.0 / 5 |
| Mochi Health | $178 (compounded, flat) | $278 (compounded, flat) | B-, 1,296 complaints | ~4.0 ★ / 12,900+ | 3.0 / 5 |
| Hims | $348 (brand Wegovy Pen) | $2,048 (brand Zepbound) | A+, 3,792 complaints | 3.0 ★ / 7,794 | 2.5 / 5 |
Semaglutide monthly total for Mochi includes the $79 membership and $99 medication charge billed as separate subscriptions. Henry Meds' $297 figure reflects the injectable-semaglutide checkout quote cross-referenced across independent 2026 reviewer accounts, versus the $179 homepage headline that applies to liraglutide or to a twelve-month prepay commitment. Hims sells brand-name FDA-approved products only as of April 2026, with $149/month membership billed separately from medication; Hims' semaglutide column is Wegovy Pen and Hims' tirzepatide column is Zepbound, priced at list.
What we look at in every review
Every provider review covers the same ten areas, in the same order, so two reviews can be compared line by line:
- Headline price vs. real price. The marketing-page rate, then the actual checkout quote at the standard starting dose for injectable semaglutide, injectable tirzepatide, and any oral alternatives the provider offers.
- Dose-escalation fees. Whether the price changes as the patient titrates from 0.25 mg up to maintenance, and how much.
- Commitment-tier pricing. Three-month, six-month, and twelve-month prepay options, the effective monthly rate at each tier, and the refund language the provider publishes or omits.
- What is and isn't included. Provider visits, medication, needles and supplies, shipping, and whether insurance is billed or accepted.
- Provider panel. Board-certified obesity-medicine claims, state licensure scope, whether a specific prescribing provider is named, and who owns the affiliated compounding pharmacy.
- Compounding pharmacy. 503A vs. 503B classification, independent pharmacy vs. owned-and-operated, any state-level board actions or immediate-jeopardy findings.
- Regulatory record. FDA Warning Letters Database check on the retrieval date, BBB letter grade and three-year complaint volume with dominant categories, Trustpilot volume and average.
- Litigation. Active Eli Lilly and Novo Nordisk cases, their procedural status, and what claims survived motions to dismiss. Treated as context, not a patient-safety signal.
- Shipping cadence and cold chain. First-shipment timeline, refill cadence, any documented cold-chain failures or replacement pharmacy events.
- Cancellation and refund mechanics. Where to cancel, whether membership and medication are billed together or separately, and what the provider's written policy says about refunds on prepay plans.
How we cover provider reviews
Every review follows the standards described in our editorial policy. Every specific numerical or factual claim is verified live against a primary source in the drafting session: the provider's own marketing and FAQ pages, the FDA Warning Letters Database, BBB business profiles, Trustpilot, state Department of Health records, court filings and rulings, and manufacturer pricing via NovoCare Direct and LillyDirect. Every retrieval date is recorded in each review's Sources section.
We do not accept affiliate payments, sponsorship, or directed coverage in exchange for editorial content, on provider reviews or anywhere else on the site. To suggest a provider for review or report a factual error, email editorial@healthymealsincentives.org. Corrections are reviewed within five business days.
Frequently Asked Questions
How do you pick which providers to review?
We prioritize providers patients are actively evaluating: cash-pay compounded-GLP-1 companies with meaningful market presence, a public pricing structure, and enough operating history to have a complaints record. We do not accept payment to influence the assessment in any review, including the one with a disclosed partnership. Suggestions are welcome at editorial@healthymealsincentives.org.
Do you take affiliate commissions on these reviews?
Some. Each review carries a partnership badge at the top. Reviews labeled "Disclosed Partnership" may earn us a commission when readers enroll through the links on that page; the price the reader pays does not change, and the editorial assessment is independent of the partnership. Reviews labeled "No Affiliate Relationship" (Henry Meds, Hims, Mochi at the time of writing) carry no commission or referral arrangement of any kind. Our pillar and explainer pages carry no affiliate links. Our editorial policy governs sourcing, expert review, and correction standards across all reviews.
How do you verify the pricing you publish?
Headline rates come from the provider's own marketing pages, fetched and dated in the review. Real checkout and dose-escalation pricing is cross-referenced across multiple independent reviewer accounts, because most providers do not publish full tiered pricing publicly. Brand-name comparison pricing comes from manufacturer sources: NovoCare Direct for Wegovy and Ozempic, LillyDirect for Zepbound and Mounjaro. Every retrieval date is recorded in the review's Sources section.
What regulatory signals do you look at?
FDA warning letters, BBB complaint volume and pattern, Trustpilot review volume and average, state-level pharmacy board actions against the provider or its affiliated compounding pharmacy, and active litigation from Eli Lilly and Novo Nordisk. Industry-wide manufacturer lawsuits are reported once per review and not treated as a customer-safety signal; state-level actions against a provider's own pharmacy are.
Does a compounded medication mean the provider is not legitimate?
No. Compounding is a regulated practice under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. After the FDA declared the semaglutide and tirzepatide shortages resolved, licensed 503A and 503B pharmacies continued to produce personalized or combination formulations under a narrower regulatory pathway. Compounded is not a synonym for illegitimate. Our reviews separate the regulatory framework from the conduct of the specific provider.
Written By
Rachel Nguyen, MS, RDN
Rachel is a registered dietitian with over a decade of experience in nutrition policy and the economics of health. Her current editorial focus covers GLP-1 medications, obesity medicine, and the intersection of nutrition and pharmaceutical treatment. She holds a Master of Science in Nutrition from the University of North Carolina.
Expert Reviewer
Dr. Kevin Park, PhD
Dr. Park is a nutrition education researcher focused on federal nutrition programs and dietary outcomes. His work has been published in the Journal of School Health and the Journal of the Academy of Nutrition and Dietetics. He reviewed this hub's methodology and editorial framework. Clinical decisions about GLP-1 therapy should be made with a licensed prescriber.